Polycystic Ovary Syndrome Renamed Polyendocrine Metabolic Ovarian Syndrome

The condition previously known as polycystic ovary syndrome, or PCOS, has been renamed polyendocrine metabolic ovarian syndrome, or PMOS. A global consensus statement published in The Lancet on May 12, 2026, established the new name after a process that included 56 academic, clinical and patient organizations and input from more than 14,300 people worldwide.

com. The new designation seeks to describe the full range of hormonal, metabolic and reproductive features involved rather than centering on ovarian cysts that are not present in every case. "It acknowledges the complex multi-organ system aspects of the condition," said Dr.

Shruthi Mahalingaiah, faculty in the Division of Reproductive Endocrinology and Infertility at Massachusetts General Hospital. The condition affects up to 10 percent of women in their reproductive years.

Criteria have changed over time, with guidelines issued by the NIH in 1990, the Rotterdam criteria in 2003 and the Androgen Excess Society criteria in 2006. The same patient could qualify under one set of standards and not another. Hormone testing lacks a universal standard, with reference ranges varying across laboratories and many assays originally developed for male hormone levels.

Ultrasound thresholds for polycystic ovaries have shifted from 10 follicles to 12 to 19 or more depending on available technology. In adolescents, irregular cycles and multifollicular ovaries are often normal aspects of puberty, complicating early identification.

What the New Name Reflects The term "polyendocrine" recognizes multiple interacting hormonal pathways, including insulin, androgens and neuroendocrine signals. "Metabolic" highlights core features such as insulin resistance, weight changes and elevated cardiovascular risk.

"Ovarian" retains the connection to reproductive issues including irregular cycles, ovulation disruption and fertility challenges while removing emphasis on cysts. Symptoms vary widely across patients. Reproductive effects can include irregular or absent periods, excess facial or body hair, scalp hair thinning and infertility.

Metabolic effects may involve insulin resistance, weight gain, difficulty losing weight, dark velvety skin patches, and increased risk of prediabetes, type 2 diabetes and cardiovascular disease. Additional symptoms can include severe acne, oily skin, persistent fatigue, anxiety and depression.

These have often been treated by separate specialists as unrelated issues. The new name encourages clinicians to view them as connected to a single underlying condition.

"There is increased awareness of the multi-organ systems affected by this condition," said Mahalingaiah. Patient advocacy contributed support for the international effort. The process required extensive time to build consensus across research and clinical teams.

The updated name is intended to influence diagnosis, treatment, research funding and public understanding of the condition. Long-term health management may improve through better education and preventive care focused on metabolic and cardiovascular risks.